A Study of SPY072 in Rheumatic Disease
Launched by SPYRE THERAPEUTICS, INC. ·
Trial Information
Current as of September 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medicine called SPY072 to see if it helps adults with different types of rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. These are conditions that cause pain, swelling, and stiffness in the joints. The study aims to find out if SPY072 is safe and effective compared to a placebo, which is a treatment without the active medicine. The trial is currently recruiting adults aged 18 and older, of any gender, who have one of these rheumatic diseases.
If you join the study, you will be randomly assigned to receive either SPY072 or a placebo, and neither you nor the study team will know which one you are getting until the study ends. This helps make the results more reliable. The study will take place at several medical centers, and you will have regular check-ups to monitor your health and symptoms. Participating means helping researchers learn more about this potential new treatment, which could benefit people with rheumatic diseases in the future.
Gender
ALL
Eligibility criteria
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is an innovative biopharmaceutical company dedicated to advancing the treatment of complex diseases through the development of cutting-edge therapeutics. With a strong focus on harnessing novel drug discovery approaches and precision medicine, Spyre Therapeutics aims to address unmet medical needs in various therapeutic areas, including oncology and rare diseases. The company is committed to rigorous clinical research and collaboration with healthcare professionals to ensure the safety and efficacy of its investigational therapies, ultimately striving to improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
SKYWAY-RD Study Director
Study Director
Spyre Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported